Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MICRODYN-NADIR was a German membrane technology company focused on filtration products for water, wastewater, and industrial process applications rather than therapeutics. The business developed and manufactured membrane products and modules across microfiltration, ultrafiltration, nanofiltration, reverse osmosis, and membrane bioreactor technologies. It served municipal, industrial, life science process, desalination, and other fluid treatment markets. MANN+HUMMEL acquired full ownership in 2015, and in 2021 the MICRODYN-NADIR business was rebranded as MANN+HUMMEL Water & Fluid Solutions, now presented as MANN+HUMMEL Water & Membrane Solutions. For biotech analysts, this is best understood as an industrial/life-science-enabling filtration and process technology business, not a drug developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MICRODYN-NADIR.